Myriad and Ambry face off at appeals court


A US appeals court has heard oral arguments in a case between Myriad Genetics and a generics company it wants to prevent from marketing its own test for BRCA gene mutations that can lead to breast cancer.

Myriad, Ambry, BRCA, patent